Editas Medicine became the exclusive licensee of Broad Institute's Cas12a patent estate.
2 reports, 1 independent
Updated Aug 29
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Editas Medicine became the exclusive licensee of Broad Institute's Cas12a patent estate.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Editas Medicine
discovery-phase pharmaceutical company
Nothing else this week.
-
Broad Institute
biomedical and genomic research center
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireEditas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing compa
- GlobeNewswireEditas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on